Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of QBKPN Site-Specific Immunomodulator (SSI) Efficacy in Improving Innate Immune Function and Reducing All-Cause Respiratory Tract Infection Morbidity in Adults 65 Years of Age of Older Residing in Independent-Living, Assisted-Living and Long-term Care Facilities

Next Previous
Trial Profile

Assessment of QBKPN Site-Specific Immunomodulator (SSI) Efficacy in Improving Innate Immune Function and Reducing All-Cause Respiratory Tract Infection Morbidity in Adults 65 Years of Age of Older Residing in Independent-Living, Assisted-Living and Long-term Care Facilities

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QBKPN (Primary)
  • Indications Immunodeficiency disorders; Respiratory tract infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms RESILIENCE
  • Sponsors Qu Biologics

Most Recent Events

  • 23 Jul 2025 According to a Qu Biologics media release, company announced that they have completed enrolment of all 72 participants in this trial.
  • 23 Jul 2025 Status changed from recruiting to active, no longer recruiting.
  • 22 Jan 2025 Planned End Date changed from 1 Jul 2025 to 1 Feb 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top